Antibodies have proven to be an excellent ... The future of all small single domains is clearly to provide new binding specificities, particularly to targets inaccessible to conventional antigen ...

Single-domain intracellular antibodies are antibody variable segments that bind to specific target proteins inside cells. These antigen-binding variable regions can interfere with protein function ...

Allen Guo, CEO "We are excited to present our pre-clinical findings at the AACR, showcasing the significant potential of our CD3 agonistic single-domain antibody," said Allen Guo, CEO.

Originally derived from camelid heavy chain antibodies, single domain or VHH antibodies can bind epitopes that are inaccessible to conventional monoclonal antibodies due to their small size. Because ...

Single-domain antibodies, or nanobodies, have recently been thrust into the spotlight as a potential treatment for COVID-19. In fact, a COVID-19 nanobody-based treatment developed by the Beroni ...

Single domain antibodies (AKA nanobodies), the variable domains of some camelid antibodies, have interesting properties, including high production yields and stability but also the ability to bind ...

Valour Bio has been established as a wholly owned subsidiary of Valerio Therapeutics to focus on discovering single domain antibodies (sdAbs) as drug and radio conjugates, bispecific T-cell ...

Since the discovery of camelid heavy chain antibodies in the early 90’s, the use of their pared down version, known as single domain antibodies (sdAbs) or VHH ligands, has seen a tremendous uptake in ...

The antibody therapeutics industry is growing at an incredible pace. From early monoclonal therapeutic antibodies to modern bispecific and multispecific antibodies, single domain antibodies (VHHs ...